Resistance mechanisms to cancer chemotherapy

被引：92

作者：

Redmond, Kelly Marie ^{[1
]}

Wilson, Timothy Richard ^{[1
]}

Johnston, Patrick Gerard ^{[1
]}

Longley, Daniel Broderick ^{[1
]}

机构：

[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Drug Resistance Lab, Belfast, Antrim, North Ireland

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2008年 / 13卷

基金：

英国医学研究理事会;

关键词：

chemotherapy; drug resistance; molecular-targeted therapy; review;

D O I：

10.2741/3070

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Resistance to chemotherapy ('drug resistance') is a fundamental problem that limits the effectiveness of many chemotherapies currently used to treat cancer. Drug resistance can occur due to a variety of mechanisms, such as increased drug inactivation, drug efflux from cancer cells, enhanced repair of chemotherapy-induced damage, activation of pro-survival pathways and inactivation of cell death pathways. In this article, we review some of the major mechanisms of drug resistance and discuss how new molecularly-targeted therapies are being increasingly used to overcome these resistance mechanisms.

引用

页码：5138 / 5154

页数：17

共 164 条

[1]

Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro [J].